pharma news, views and analysis

in Sales and Marketing
Metrics to meaning: demonstrating the value of medical communications
November 14, 2018 Share
X
Metrics to meaning: demonstrating the value of medical communications
https://pharmaphorum.com/sales-marketing/metrics-to-meaning-demonstrating-the-value-of-medical-communications/
in News
Takeda mulling sale of emerging market drugs – report
January 22, 2019 Share
X
Takeda mulling sale of emerging market drugs – report
https://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
in News
US cancer patients trial Proteus’ digital chemotherapy pill
January 22, 2019 Share
X
US cancer patients trial Proteus’ digital chemotherapy pill
https://pharmaphorum.com/news/us-cancer-patients-trial-proteus-digital-chemotherapy-pill/
in Views & Analysis
Rethinking adherence programmes
January 22, 2019 Share
X
Rethinking adherence programmes
https://pharmaphorum.com/views-analysis-digital/rethinking-adherence-programmes/
in Views & Analysis
JP Morgan Healthcare: where science, tech and finance collide
January 21, 2019 Share
X
JP Morgan Healthcare: where science, tech and finance collide
https://pharmaphorum.com/views-analysis-sales-marketing/jp-morgan-healthcare-science-tech-finance-collide/

Latest News

Novo Holdings invests in three more AMR biotechs

Novo Holdings’ REPAIR Impact Fund, which helps fund companies tackling antimicrobial resistance (AMR), has announced three new investments.

Novo Holdings invests in three more AMR biotechs

https://pharmaphorum.com/news/novo-holdings-invests-in-three-more-amr-biotechs/

FDA approves Samsung/Merck & Co’s Herceptin biosimilar

The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck

FDA approves Samsung/Merck & Co’s Herceptin biosimilar

https://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

https://pharmaphorum.com/news/abbvie-and-jjs-imbruvica-fails-pancreatic-cancer-test/

See all

Views & analysis

Opening doors in pharmaceutical development

Evidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase

Opening doors in pharmaceutical development

https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/machine-learning-opening-doors-in-pharmaceutical-development/

Digital health round-up: J&J joins with Apple and more AI deals

Richard Staines presents a round-up of the recent major developments in the field of digital health

Digital health round-up: J&J joins with Apple and more AI deals

https://pharmaphorum.com/views-analysis-digital/digital-health-jj-joins-with-apple-more-ai-deals/

Expanding the definition of medicine

Digital therapeutics are adding new elements to the medical world, but their place in the pharmaceutical sector is

Expanding the definition of medicine

https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/digital-therapeutics-expanding-the-definition-of-medicine/

See all

Deep Dive Magazine

Deep Dive: Disruptive Technologies

In the first issue of Deep Dive for 2019, we look at disruptive technologies in pharma, how they’re

Deep Dive: Disruptive Technologies

https://pharmaphorum.com/digital/disruptive-technologies-pharma-2019/

European digital health innovation

Healthcare and the pharmaceutical industry are redefining their roles for the modern age as digital health tech radically

European digital health innovation

https://pharmaphorum.com/digital/european-digital-health-innovation/

CAR-Ts – a new weapon in the fight against cancer

CAR-T – or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer. CAR-T therapies

CAR-Ts – a new weapon in the fight against cancer

https://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/

See all

Webinars

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

https://pharmaphorum.com/market-access-2/the-2nd-life-sciences-sector-deal-and-the-nhs-10-year-plan/

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

Metrics to meaning: demonstrating the value of medical communications

https://pharmaphorum.com/sales-marketing/metrics-to-meaning-demonstrating-the-value-of-medical-communications/

See all

White papers

Designing behavioural science-based patient support programmes

We all exhibit behaviours that are, at times, irrational, and this presents a major challenge for pharmaceutical companies

Designing behavioural science-based patient support programmes

https://pharmaphorum.com/sales-marketing/designing-behavioural-science-based-patient-support-programmes/

Adherence – Don’t Remind Me!

The benefits of adherent patients are no secret: better outcomes, a more stable treatment pathway and of course

Adherence – Don’t Remind Me!

https://pharmaphorum.com/sales-marketing/adherence-dont-remind-me/

Intelligent HCP engagement in Europe – what do doctors want?

The opportunity to engage with HCPs digitally has never been more prevalent. We are witnessing a desire from

Intelligent HCP engagement in Europe – what do doctors want?

https://pharmaphorum.com/digital/intelligent-hcp-engagement-europe/

See all

Video

Biotech strategy and nanomedicine: the pharmaphorum podcast

https://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/

The future of pharma in a digital world

https://pharmaphorum.com/digital/healthlive-the-future-of-pharma-in-a-digital-world/

Raising the bar in liver cancer therapy

https://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/

See all

Partner content

Press releases

Appointments

pharmaphorum welcomes George Underwood to its editorial helm

https://pharmaphorum.com/news/pharmaphorum-welcomes-george-underwood-to-its-editorial-helm/

STEM Healthcare appoints Jason McKenna as CEO

https://pharmaphorum.com/partner-content/stem-healthcare-appoints-jason-mckenna-as-ceo/

See all

Trending

Metrics to meaning: demonstrating the value of medical communications

Takeda mulling sale of emerging market drugs – report

US cancer patients trial Proteus’ digital chemotherapy pill

Rethinking adherence programmes

JP Morgan Healthcare: where science, tech and finance collide

Latest News

Novo Holdings invests in three more AMR biotechs

FDA approves Samsung/Merck & Co’s Herceptin biosimilar

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

Views & analysis

Opening doors in pharmaceutical development

Digital health round-up: J&J joins with Apple and more AI deals

Expanding the definition of medicine

Deep Dive Magazine

Deep Dive: Disruptive Technologies

European digital health innovation

CAR-Ts – a new weapon in the fight against cancer

Webinars

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

Cancer, genomics and personalised medicine: Modelling oncology’s future

Metrics to meaning: demonstrating the value of medical communications

White papers

Designing behavioural science-based patient support programmes

Adherence – Don’t Remind Me!

Intelligent HCP engagement in Europe – what do doctors want?

Video

Biotech strategy and nanomedicine: the pharmaphorum podcast

The future of pharma in a digital world

Raising the bar in liver cancer therapy

Partner content

Press releases

Invite from Roderick Hubbard, Vernalis Research chairing SMi’s Drug Discovery Conference

Pharmaceutical Microbiology UK CONFEX takes place in less than a week!

Tom Parke to lead a workshop on the new FDA draft guidance

Three-dimensional cell cultures as predictive tools in early drug discovery

Appointments

pharmaphorum welcomes George Underwood to its editorial helm

STEM Healthcare appoints Jason McKenna as CEO

Search

Advanced Search

Trending

Press releases

Appointments